Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

60.25USD
9:02pm BST
Change (% chg)

$1.42 (+2.41%)
Prev Close
$58.83
Open
$60.06
Day's High
$60.62
Day's Low
$59.43
Volume
5,386,926
Avg. Vol
3,918,603
52-wk High
$66.41
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $176,050.70
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.91

Financials

  MRK.N Industry Sector
P/E (TTM): 35.16 30.95 32.74
EPS (TTM): 1.84 -- --
ROI: 6.58 14.84 14.38
ROE: 12.28 16.34 16.07

BRIEF-EMA Validates Type II Variation For Merck's Keytruda In Combination With Pemetrexed And Platinum Chemotherapy

* EUROPEAN MEDICINES AGENCY VALIDATES TYPE II VARIATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY AS FIRST-LINE THERAPY IN METASTATIC NONSQUAMOUS NSCLC, BASED ON PHASE 3 KEYNOTE-189 TRIAL Source text for Eikon: Further company coverage:

9:46pm BST

US STOCKS-Wall St little changed as bond yields inch higher

* Indexes: Dow and Nasdaq flat, S&P up 0.13 pct (Updates to early afternoon)

7:09pm BST

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine

* MERCK ANNOUNCES FIRST PHASE THREE STUDIES FOR PCV-15 (V114) ITS INVESTIGATIONAL PNEUMOCOCCAL DISEASE VACCINE

17 Apr 2018

BRIEF-Labcyte Reaches Agreement With Merck To Supply Acoustic-Mass Spectrometry Equipment

* LABCYTE REACHES AGREEMENT WITH MERCK TO SUPPLY ACOUSTIC-MASS SPECTROMETRY EQUIPMENT

17 Apr 2018

Survival data boosts Merck's Keytruda lead in lung cancer

NEW YORK/CHICAGO Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

16 Apr 2018

UPDATE 2-Survival data boosts Merck's Keytruda lead in lung cancer

NEW YORK/CHICAGO, April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

16 Apr 2018

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.

16 Apr 2018

Competitors

Earnings vs. Estimates